Phreesia, Inc. (NYSE:PHR) Receives $31.15 Average Price Target from Brokerages

Shares of Phreesia, Inc. (NYSE:PHR) have received an average recommendation of “Buy” from the thirteen analysts that are covering the firm, Marketbeat Ratings reports. Thirteen equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $31.15.

A number of research firms have commented on PHR. Truist Financial boosted their price target on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and boosted their price target for the stock from $24.00 to $32.00 in a research note on Wednesday, January 8th. JMP Securities reissued a “market outperform” rating and issued a $30.00 price target on shares of Phreesia in a research note on Tuesday, December 10th. Robert W. Baird cut their price target on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $29.00 price target on shares of Phreesia in a research note on Friday, January 10th.

Insider Activity

In related news, SVP Amy Beth Vanduyn sold 1,311 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $26.61, for a total transaction of $34,885.71. Following the completion of the sale, the senior vice president now directly owns 115,633 shares in the company, valued at $3,076,994.13. This represents a 1.12 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Michael Weintraub sold 20,565 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $25.04, for a total transaction of $514,947.60. Following the sale, the director now owns 242,827 shares of the company’s stock, valued at $6,080,388.08. This represents a 7.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 195,740 shares of company stock valued at $5,441,409. Corporate insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Phreesia

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Versor Investments LP bought a new stake in Phreesia during the 3rd quarter valued at $694,000. Zacks Investment Management bought a new position in Phreesia in the 3rd quarter worth $631,000. State Street Corp raised its holdings in Phreesia by 7.1% in the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock worth $30,256,000 after purchasing an additional 88,517 shares in the last quarter. Wesbanco Bank Inc. raised its holdings in Phreesia by 76.9% in the 4th quarter. Wesbanco Bank Inc. now owns 46,000 shares of the company’s stock worth $1,157,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Barclays PLC raised its holdings in Phreesia by 83.6% in the 3rd quarter. Barclays PLC now owns 94,929 shares of the company’s stock worth $2,163,000 after purchasing an additional 43,225 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors.

Phreesia Price Performance

Shares of NYSE:PHR opened at $23.69 on Friday. The company has a 50 day moving average of $27.45 and a 200 day moving average of $24.02. The stock has a market cap of $1.38 billion, a P/E ratio of -16.12 and a beta of 1.03. Phreesia has a 12 month low of $17.07 and a 12 month high of $30.53. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04.

Phreesia (NYSE:PHR) last released its quarterly earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The business had revenue of $106.80 million during the quarter, compared to analysts’ expectations of $106.33 million. During the same quarter in the previous year, the company earned ($0.58) EPS. The business’s quarterly revenue was up 16.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Phreesia will post -1.1 EPS for the current fiscal year.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.